Compare Invesco Galaxy Bitcoin ETF (BTCO) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Galaxy Bitcoin ETF vs Quest Diagnostics Inc — how do they compare? Invesco Galaxy Bitcoin ETF trades at $64.69, while Quest Diagnostics Inc trades at $202.51 (market cap $22.80B). The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Invesco Galaxy Bitcoin ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BTCO | DGX | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $125.14 | $216.02 |
52-Week Low | $58.40 | $166.42 |
Market Cap | — | $22.80B |
Enterprise Value | — | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTCO trades at $61.86, down 2.67% today amid mixed technical signals with a bullish overall trend but bearish moving averages. The stock faces resistance near $64-65 while finding support around $62-63. Financial ratios remain unavailable in current data, requiring deeper fundamental analysis.
The stock shows technical resilience despite recent selling pressure, with key support levels holding. Investment appeal depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and competitive pressures in its sector.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
